derazantinib (ARQ 087) / Merck (MSD), Roivant  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
derazantinib (ARQ 087) / Merck (MSD)
NCT04087876: Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Available
N/A
NA
derazantinib
Basilea Pharmaceutica
Intrahepatic Cholangiocarcinoma
 
 
ChiCTR2000031787: A Clinical Study to Evaluate Safety and Efficacy of ARQ 087 in Chinese Inoperable, Recurrent or Metastatic Intrahepatic Cholangiocarcinoma Subjects With Advanced Solid Tumors and FGFR2 Gene Fusion Positive Who Failed at Least First-Line Systemic Therapy

Recruiting
N/A
110
 
ARQ087 ;ARQ087
Peking University Cancer Hospital & Institute; Sinovant Sciences Co., Ltd., self-financing
Solid Tumor and Intrahepatic Cholangiocarcinoma
 
 

Download Options